ArticlePhysiological genomics2019
Different blood pressure responses in hypertensive rats following chemerin mRNA inhibition in dietary high fat compared to dietary high-salt conditions.
Article in Physiological genomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Tissue-Specific Chemerin in Atherosclerosis.Biomolecules · 2026Review
- Chemerin as a Driver of Cardiovascular Diseases: New Perspectives and Future Directions.Biomedicines · 2025Review
- Vascular effects of perivascular adipose tissue-derived chemerin in obesity-associated cardiovascular disease.Cardiovascular diabetology · 2025Review
- Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.Biomedicines · 2025Article
- Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives.Journal of clinical medicine · 2024Review
- Chemerin in the Spotlight: Revealing Its Multifaceted Role in Acute Myocardial Infarction.Biomedicines · 2024Review
- Novel role of vascular chemerin in blood vessel tone.American journal of physiology. Heart and circulatory physiology · 2023Article
- Chemerin is resident to vascular tunicas and contributes to vascular tone.American journal of physiology. Heart and circulatory physiology · 2023Article
- Review
- Adipokines: Deciphering the cardiovascular signature of adipose tissue.Biochemical pharmacology · 2022Review
- Role of Chemerin in Cardiovascular Diseases.Biomedicines · 2022Review
- A high fat diet does not stimulate blood pressure dependence on chemerin in the Sprague-Dawley rat.American heart journal plus : cardiology research and practice · 2022Article
- Chemerin Forms: Their Generation and Activity.Biomedicines · 2022Review
- Divergence of Chemerin Reduction by an ATS9R Nanoparticle Targeting Adipose Tissue In Vitro vs. In Vivo in the Rat.Biomedicines · 2022Article
- Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction.Journal of translational medicine · 2022Review
- Salt-Sensitivity of Blood Pressure and Insulin Resistance.Frontiers in physiology · 2021Review
- Chemerin as a Driver of Hypertension: A Consideration.American journal of hypertension · 2020Review
- Adipokines and Inflammation: Focus on Cardiovascular Diseases.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Chemerin is a contractile adipokine, produced in liver and fat, and removal of the protein by antisense oligonucleotides (ASO) lowers blood pressure in the normal Sprague Dawley rat. In humans, chemerin is positively associated with blood pressure and obesity so we hypothesized that in a model of hypertension derived from high-fat (HF) feeding, the chemerin ASO would reduce blood pressure more than a high-salt (HS) model. Male Dahl S rats were given a HF (60% kcal fat; age 3-24 wk) or HS diet (4% salt; age 20-24 wk to match age and blood pressure of HF animals). Scrambled control, whole body, or liver-specific ASOs that knock down chemerin were delivered subcutaneously once per week for 4 wk with tissue and blood collected 2 days after the last injection. Conscious blood pressure was measured 24 h/day by radiotelemetry. By the end of whole body ASO administration, blood pressure of HF animals had fallen 29 ± 2 mmHg below baseline, while blood pressure of HS-diet animals fell by only 12 ± 4 mmHg below baseline. Administration of a liver-specific ASO to HF Dahl S resulted in a 6 ± 2 mmHg fall in blood pressure below baseline. Successful knockdown of chemerin in both the whole body and liver-specific administration was confirmed by Western and PCR. These results suggest that chemerin, not derived from liver but potentially from adipose tissue, is an important driver of hypertension associated with high fat. This knowledge could lead to the development of antihypertensive treatments specifically targeted to obesity-associated hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.